Stem Cell Differentiation Compounds Reducing Production Costs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing cardiac differentiation from pluripotent stem cells are inefficient and costly, and they struggle to produce cardiomyocytes of high purity, leading to concerns about cancer contamination and donor shortages for heart failure treatment.
Innovation Solution
Development of novel compounds with different halogen groups or carbon chain lengths compared to KY02111, which promote cardiac differentiation at lower concentrations, enabling more efficient and cost-effective production of cardiomyocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If KY02111 is used to promote cardiac differentiation, then differentiation efficiency is improved, but production cost increases and purity decreases
Solution Approach 1:
The patent modifies the chemical structure of KY02111 by changing the halogen group (Cl to F, Br, or I) and/or the carbon chain length (n=1 to 6) to create compounds with different biological activities. These structural parameter changes result in compounds that achieve cardiac differentiation at lower concentrations, thereby reducing production costs while maintaining or improving differentiation efficiency and purity
2Productivity
If KY02111 is used to promote cardiac differentiation, then differentiation efficiency is improved, but cell purity worsens due to contamination with proliferating non-cardiomyocyte cells
Solution Approach 1:
By changing the halogen group and carbon chain length parameters of the compound structure, the patent creates derivatives that achieve cardiac differentiation at lower concentrations. This reduces the stimulation of non-cardiomyocyte cell proliferation while maintaining cardiomyocyte differentiation efficiency, thereby improving cell purity
3Reliability
If high concentration of KY02111 is used, then sufficient cardiac differentiation is achieved, but production cost increases
Solution Approach 1:
The patent creates compound derivatives with modified halogen groups and carbon chain lengths that exhibit enhanced biological activity. These structural changes enable the compounds to achieve sufficient cardiac differentiation at lower concentrations, directly reducing the amount of substance needed and thereby lowering production costs
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The disclosure relates to a compound having Formula (II) wherein m is 1 to 4, and R16 and R17 are independently selected from methoxy, ethoxy and propoxy, or a salt thereof.